中国再生医学(08158.HK)完成培训规定
格隆汇7月19日丨中国再生医学(08158.HK)公布,有关谴责公司违反联交所GEM证券上市规则第19.20、19.34及19.40条。
根据新闻稿第(1)段的指令,公司正在联络合适的专业公司,旨在于切实可行情况下尽快委任独立合规顾问。根据新闻稿第(2)及(3)段的指令,公司现任独立非执行董事陈炳焕以及公司前任执行董事戴昱敏已参加由联交所上市科接纳的认可机构所提供有关遵守GEM上市规则、董事职责及企业管治事宜的24小时培训连同有关GEM上市规则第十九章及附录十五(企业管治守则)合规的四小时培训(合共28小时)。
由上述机构所发出确认陈炳焕及戴昱敏已出席培训的书面证明已提供予联交所上市科。在新闻稿内所确定有关人士中,陈炳焕为公司唯一的现任董事。由于陈炳焕已遵守新闻稿第(2)段的指令,故公司确认已遵守上述有关公司现任董事的指令。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.